224 related articles for article (PubMed ID: 18809605)
1. Late congestive heart failure after hematopoietic cell transplantation.
Armenian SH; Sun CL; Francisco L; Steinberger J; Kurian S; Wong FL; Sharp J; Sposto R; Forman SJ; Bhatia S
J Clin Oncol; 2008 Dec; 26(34):5537-43. PubMed ID: 18809605
[TBL] [Abstract][Full Text] [Related]
2. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.
Armenian SH; Ding Y; Mills G; Sun C; Venkataraman K; Wong FL; Neuhausen SL; Senitzer D; Wang S; Forman SJ; Bhatia S
Br J Haematol; 2013 Oct; 163(2):205-13. PubMed ID: 23927520
[TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.
Armenian SH; Sun CL; Shannon T; Mills G; Francisco L; Venkataraman K; Wong FL; Forman SJ; Bhatia S
Blood; 2011 Dec; 118(23):6023-9. PubMed ID: 21976673
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Heart failure after allogeneic hematopoietic stem cell transplantation.
Mo XD; Xu LP; Liu DH; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Wang FR; Wang JZ; Zhao T; Yan CH; Sun YQ; Liu KY; Huang XJ
Int J Cardiol; 2013 Sep; 167(6):2502-6. PubMed ID: 22727962
[TBL] [Abstract][Full Text] [Related]
6. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation.
Armenian SH; Sun CL; Mills G; Teh JB; Francisco L; Durand JB; Wong FL; Forman SJ; Bhatia S
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1138-44. PubMed ID: 20197101
[TBL] [Abstract][Full Text] [Related]
7. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
9. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
10. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction.
Fujimaki K; Maruta A; Yoshida M; Sakai R; Tanabe J; Koharazawa H; Kodama F; Asahina S; Minamizawa M; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Bone Marrow Transplant; 2001 Feb; 27(3):307-10. PubMed ID: 11277179
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
12. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
14. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
Majhail NS; Challa TR; Mulrooney DA; Baker KS; Burns LJ
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
[TBL] [Abstract][Full Text] [Related]
15. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).
Wood WA; Le-Rademacher J; Syrjala KL; Jim H; Jacobsen PB; Knight JM; Abidi MH; Wingard JR; Majhail NS; Geller NL; Rizzo JD; Fei M; Wu J; Horowitz MM; Lee SJ
Cancer; 2016 Jan; 122(1):91-8. PubMed ID: 26439325
[TBL] [Abstract][Full Text] [Related]
18. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
[TBL] [Abstract][Full Text] [Related]
20. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
